Effects of intraduodenal administration of tarazepide on pancreatic secretion and duodenal EMG in neonatal calves

R Zabielski, Violetta Naughton, J Borlak, PC Gregory, P Kiela, SG Pierzynowski, W Barej

Research output: Contribution to journalArticlepeer-review

33 Citations (Scopus)

Abstract

The influence of CCK-A receptor antagonism on pancreatic exocrine secretion and duodenal EMG, and the mechanism(s) involved in CCK-induced pancreatic secretion were studied in conscious calves. Seven 1-week-old calves were fitted with a pancreatic duct catheter, duodenal cannula and duodenal electrodes. Pancreatic exocrine secretion and duodenal EMG were studied following intraduodenal CCK-A receptor antagonist (Tarazepide), intravenous atropine, and intravenous or intraduodenal CCK-8 administrations. Tarazepide decreased duodenal electric activity, reduced interdigestive pancreatic secretion, especially protein; reduced cephalic and early postprandial (milk) induced secretion of bicarbonate and protein. Pancreatic protein secretion to intravenous CCK-8 was little affected by atropine, but was significantly reduced by Tarazepide+/-atropine; in contrast, protein secretion to intraduodenal CCK-8 was abolished by Tarazepide or atropine. We conclude that pre- and especially early postprandial pancreatic secretion are partly controlled via CCK-A (mainly mucosal) mediated mechanisms. (C) 1998 Elsevier Science B.V. All rights reserved.
Original languageEnglish
Pages (from-to)113-123
JournalRegulatory Peptides
Volume78
Issue number1-3
Publication statusPublished (in print/issue) - Nov 1998

Fingerprint

Dive into the research topics of 'Effects of intraduodenal administration of tarazepide on pancreatic secretion and duodenal EMG in neonatal calves'. Together they form a unique fingerprint.

Cite this